Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation

  • ACS Med Chem Lett. 2011 Oct 13;2(10):780-785. doi: 10.1021/ml200158b.
Pasha M Khan ,  Ricardo G Correa ,  Daniela B Divlianska ,  Satyamaheshwar Peddibhotla ,  E Hampton Sessions ,  Gavin Magnuson ,  Brock Brown ,  Eigo Suyama ,  Hongbin Yuan ,  Arianna Mangravita-Novo ,  Michael Vicchiarelli ,  Ying Su ,  Stefan Vasile ,  Layton H Smith ,  Paul W Diaz ,  John C Reed ,  Gregory P Roth
Abstract

NOD1 (nucleotide-binding oligomerization domain 1) protein is a member of the NLR (NACHT and leucine rich repeat domain containing proteins) protein family, which plays a key role in innate immunity as a sensor of specific microbial components derived from Bacterial peptidoglycans and induction of inflammatory responses. Mutations in NOD proteins have been associated with various inflammatory diseases that affect NF-κB (nuclear factor κB) activity, a major signaling pathway involved in Apoptosis, inflammation, and immune response. A luciferase-based reporter gene assay was utilized in a high-throughput screening program conducted under the NIH-sponsored Molecular Libraries Probe Production Center Network program to identify the active scaffolds. Herein, we report the Chemical Synthesis, structure-activity relationship studies, downstream counterscreens, secondary assay data, and pharmacological profiling of the 2-aminobenzimidazole lead (compound 1c, ML130) as a potent and selective inhibitor of NOD1-induced NF-κB activation.